The latest price target for EyePoint Pharmaceuticals (NASDAQ:EYPT) was reported by Citigroup on January 7, 2025. The analyst firm set a price target for $33.00 expecting EYPT to rise to within 12 months (a possible 331.37% upside). 20 analyst firms have reported ratings in the last year.

The latest analyst rating for EyePoint Pharmaceuticals (NASDAQ:EYPT) was provided by Citigroup, and EyePoint Pharmaceuticals initiated their buy rating.

There is no last upgrade for EyePoint Pharmaceuticals

There is no last downgrade for EyePoint Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of EyePoint Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for EyePoint Pharmaceuticals was filed on January 7, 2025 so you should expect the next rating to be made available sometime around January 7, 2026.

While ratings are subjective and will change, the latest EyePoint Pharmaceuticals (EYPT) rating was a initiated with a price target of $0.00 to $33.00. The current price EyePoint Pharmaceuticals (EYPT) is trading at is $7.65, which is within the analyst’s predicted range.